Moderna stock joins Nasdaq-100 as Citi raises target to USD 80

Published on 10/03/2026 at 21:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna stock enters the Nasdaq-100 on October 9, 2026, while Citi sets a USD 80 target after a Sell downgrade. Q2 revenue reached USD 145 million.

Isometrische 3D-Grafik zeigt Pharma-Wertschöpfungskette von Labor bis Krankenhaus — Moderna Inc. (US60770K1034) illustriert die isometrische Wertschöpfungskette der Biotech-Branche von Forschung bis zur finalen Auslieferung, Illustration mit AI erstellt.

Moderna stock (ISIN US60770K1079) closed at USD 190.01 on Nasdaq on October 2, 2026, after rising USD 1.07, or 0.57 percent, during the session. The immediate catalyst is index inclusion: Finanznachrichten reported that Nasdaq will add Moderna before market open on October 9, 2026.

Index entry changes the setup

The Nasdaq-100 tracks 100 of the largest non-financial companies listed on Nasdaq, and the index provider said products tracking the benchmark hold more than USD 800 billion in assets. Moderna will replace Warner Bros. Discovery in the index, creating a defined trading event for October 9, 2026.

That timing matters because Moderna's market capitalization stood at USD 75.4 billion on October 2, 2026. The stock's 52-week range ran from USD 22.28 to USD 208.90, placing the latest close 9.0 percent below the yearly high.

Citi raises target but cuts rating

Citi downgraded Moderna to Sell from Hold on September 30, 2026, while raising its price target to USD 80 from USD 60, according to Yahoo Finance. The new target lies 57.9 percent below the October 2 close, showing how sharply the market valuation and Citi's fundamental view have diverged.

The valuation debate centers on intismeran autogene, Moderna's personalized cancer vaccine being developed with Merck. Additional clinical data are scheduled for presentation at the European Society for Medical Oncology Congress, with Moderna's webcast set for October 24, 2026, at 1:00 p.m. EDT, per Moderna.

Q2 losses remain the counterweight

Moderna reported USD 145 million of revenue in Q2 2026, up 2 percent from the same quarter a year earlier, while adjusted loss per share was USD 1.97, according to Yahoo Finance. The company also reported a GAAP net loss of USD 782 million for the quarter.

Moderna stock stays below its yearly high

On Nasdaq, Moderna stock closed at USD 190.01 on October 2, 2026, with a session range of USD 183.28 to USD 193.72 and volume of 10,290,000 shares. The combination of Nasdaq-100 inclusion, a USD 80 Citi target and upcoming oncology data leaves index flows and clinical execution as the market's next measurable checkpoints.